Group 1 - The core viewpoint of the news is that OrbiMed (688322.SH) has reported its annual results for 2024, highlighting significant institutional investor interest and changes in shareholding patterns [1] Group 2 - As of April 21, 2025, a total of 206 institutional investors disclosed holdings in OrbiMed A-shares, with a total shareholding of 127 million shares, accounting for 31.65% of the total share capital [1] - The top ten institutional investors include Shanghai Yunxin Venture Capital Co., Ltd., Zhuhai OrbiMed Investment Partnership (Limited Partnership), and others, with their combined shareholding ratio reaching 26.51% [1] - Compared to the previous quarter, the combined shareholding ratio of the top ten institutions decreased by 3.09 percentage points [1] Group 3 - In the public fund sector, four public funds reported a decrease in holdings compared to the previous quarter, including Bank of China Securities Advantage Manufacturing Stock A and others, with a slight decline in the proportion of reduced holdings [2] - A total of 193 new public funds were disclosed this period, including several funds such as Xingquan Helun Mixed A and others [2] - One public fund, Tianhong Guozheng 2000 Index Enhanced A, was not disclosed in this period compared to the previous quarter [2]